title: Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer.
abstract: Previous studies have reported conflicting results regarding the impact of neoadjuvant chemotherapy (NAC) on estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status in breast cancer. Our aim was to investigate whether NAC induces some selective change in the breast biomarkers. We retrospectively detected the immunohistochemical results of ER, PR and HER2 between the core biopsy and surgical excision specimens in 113 patients with NAC. As a control group, we analyzed sample pairs from 102 patients without NAC. Fourteen (12.4%) of 113 patients undergoing NAC showed the ER status modulation in the surgically removed specimen as compared with only 4 (3.9%) of 102 women without NAC (p=0.025). Eighteen (15.9%) of 113 patients given NAC appeared in the PR status alteration in the final surgical specimen, whereas only 7 (6.9%) of 102 patients without NAC did (p=0.038). The HER2 status shift was found in 17 (15.0%) of 113 patients with NAC and in 6 (5.9%) of 102 patients without NAC, respectively (p=0.030). Neoadjuvant chemotherapy does change ER, PR and HER2 status in a statistically significant manner. Retesting these biomarkers of the residual tumor should be considered to improve future tailored adjuvant therapies.
authors.affiliation: Department of Pathology, The Affiliated Dongguan Shilong People's Hospital of Southern Medical University, Dongguan, Guangdong Province, China.
authors.forename: Yu-Feng
authors.initials: YF
authors.lastname: Yang
authors.forename: Ying-Yang
authors.initials: YY
authors.lastname: Liao
authors.forename: Le-Qun
authors.initials: LQ
authors.lastname: Li
authors.forename: Shu-Rui
authors.initials: SR
authors.lastname: Xie
authors.forename: Yan-Fang
authors.initials: YF
authors.lastname: Xie
authors.forename: Ning-Fu
authors.initials: NF
authors.lastname: Peng
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D012189:Retrospective Studies
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
keywords: Breast cancer; Estrogen receptor; Human epidermal growth factor receptor 2; Neoadjuvant chemotherapy; Progesterone receptor